ResMed is in a sustained downtrend, with the stock declining 18.07% over the past year compared to the S&P 500's gain of 19.1%. The current price of $209.63 sits at 71.4% of its 52-week range ($180.27 low to $293.81 high), indicating it is closer to the low end and suggesting a potential value opportunity, though the trend remains bearish. The 1-year relative strength of -37.17% underscores significant underperformance versus the market. Short-term momentum has improved markedly, with a 1-month price change of +14.66% and a 3-month change of -6.45%, showing a recent bounce from the June lows near $182.82. The 1-month relative strength of +15.91% versus the S&P 500 indicates a short-term reversal attempt, but the 3-month relative strength of -20.01% confirms the longer-term downtrend remains intact. This divergence suggests a potential mean-reversion rally within a broader bearish structure. The 52-week low of $180.27 provides key support, while the 52-week high of $293.81 is a major resistance level. A breakout above $293.81 would signal a trend reversal, while a breakdown below $180.27 could accelerate selling. With a beta of 0.775, ResMed is less volatile than the market, meaning its moves are muted relative to the S&P 500, which may appeal to risk-averse investors but also limits upside in a rally.

ResMed's revenue trajectory is accelerating, with Q2 FY2026 revenue of $1.423 billion growing 10.98% year-over-year, up from 9.8% growth in the prior quarter and 5.4% in the year-ago period. The residential care software segment contributed $166.9 million, while sleep and respiratory hardware generated $1.256 billion, indicating broad-based strength. This accelerating growth supports the investment case for a company benefiting from secular demand tailwinds. Profitability is robust, with net income of $392.6 million in Q2 FY2026 and a net margin of 27.6%, up from 26.9% in the prior quarter and 26.8% a year ago. Gross margin expanded to 62.2% from 58.6% in the same quarter last year, reflecting operating leverage and favorable mix. Operating margin of 35.0% is industry-leading for medical devices, highlighting strong pricing power and cost discipline. The balance sheet is fortress-like, with a debt-to-equity ratio of just 0.143 and a current ratio of 3.44, indicating ample liquidity. Free cash flow for the trailing twelve months is $1.789 billion, providing significant internal funding for growth and acquisitions. Return on equity of 23.5% and return on assets of 14.7% demonstrate highly efficient capital allocation and strong profitability.